Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Prothena Corporation plcNASDAQ: PRTA

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 28.6% from a year ago

Total equity stood at $312.62M at the end of Q1 FY2026, down 28.6% from a year earlier and up 11.5% from the prior quarter. Over 3 fiscal years it compounded at -23.3% a year.

Context

  • Total equity amounted to 89.3% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -28.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$312.62M+11.5% QoQ
Last fiscal yearDec 2025
$280.47M-42.4% YoY
Year agoMar 2025
$437.68M-28.6% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.6%——
1 year-42.4%——
3-year CAGR-23.3%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
280.47M USD
Year-over-year change
-42.4%
4-year CAGR
-11.9%

Total Equity vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -28.6% is the 7th highest of 10, against a peer median of -16.1%.
  • Total equity amounts to 89.3% of total assets for PRTA, versus a peer median of 72.1%.
PRTA Competitors
Total Equity for PRTA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BIIBBiogen Inc.Jun 2026$18.85B USD+6.9%+10.9%58.7%
DNLIDenali Therapeutics Inc.Jun 2026$835.18M USD-18.7%-0.9%72.1%
PRTAProthena Corporation plcMar 2026$312.62M USD-28.6%-23.3%89.3%
ANNXAnnexon, Inc.Mar 2026$204.53M USD-16.1%-2.9%77.8%
AVXLAnavex Life Sciences Corp.Dec 2025$126.62M USD+14.2%-12.7%95.2%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$87.48M USD-43.8%-28.0%65.5%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$70.68M USD-69.0%—45.9%
PMNProMIS Neurosciences, Inc.Jun 2026$49.4M USD+13012.1%—87.1%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
CGTXCognition Therapeutics, Inc.Mar 2026$29.91M USD+143.8%-5.2%82.8%
Peer median (excluding PRTA) —-16.1%-5.2%72.1%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents579.09M710.41M618.83M471.39M307.53M
Short-term Investments00000
Net Receivables13K62K5.16M00
Inventory00000
Other Current Assets766K1.71M3.49M1.17M1.75M
Total Current Assets584.81M719.1M639.28M485.41M315.19M
Property, Plant & Equipment (Net)14.14M8.01M16M13.79M10.27M
Goodwill00000
Intangible Assets00000
Long-term Investments000860K860K
Tax Assets7.07M18.2M33.89M43.24M0
Other Non-current Assets3.35M12.73M7.21M3.81M482K
Total Non-current Assets24.56M38.94M57.1M61.7M11.61M
Total Assets609.37M758.04M696.38M547.11M326.8M
Account Payables3.69M9.27M25.39M7.77M5.88M
Short-term Debt00002.89M
Tax Payables00000
Deferred Revenue7.66M11.44M08.85M2.66M
Other Current Liabilities405K503K2.13M1.38M29.42M
Total Current Liabilities33.45M50.15M56.89M48.5M40.84M
Long-term Debt00005.49M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)102.93M85.29M67.41M3.45M0
Other Non-current Liabilities553K553K00(5.49M)
Total Non-current Liabilities109.87M85.85M78.13M11.68M5.49M
Total Liabilities143.32M135.99M135.02M60.18M46.33M
Common Stock466K521K537K538K538K
Retained Earnings(716.05M)(833M)(980.03M)(1.1B)(1.35B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity466.04M622.04M561.37M486.93M280.47M
Total Debt12.33M6.47M11.84M10.84M13.86M
Net Debt(566.77M)(703.93M)(607M)(460.55M)(293.67M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.